Compare Citius Pharmaceuticals Inc (CTXR) vs Danaos Corporation (DAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Danaos Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Danaos Corporation trades at $135.01 (market cap $2.52B). The key difference: Danaos Corporation is far larger — about 134.5× Citius Pharmaceuticals Inc's market cap, and Danaos Corporation pays a 2.6% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | DAC | |
|---|---|---|
Market Cap | $18.73M | $2.52B |
Sector | Health | Technology |
52-Week High | $1.82 | $143.15 |
52-Week Low | $0.48 | $84.05 |
Enterprise Value | $14.95M | $2.50B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Danaos Corporation (DAC) trades at $140.72, down 1.7% on the day, but maintains strong technical momentum with bullish moving averages and support at $139. The company demonstrates exceptional profitability with 51.26% net income margins and trades at attractive valuations including a P/E of 4.68 and P/B of 0.62. Recent earnings beats and a record $4.6 billion contracted revenue backlog highlight operational strength.
DAC presents compelling value with deep discount to book value and consistent earnings outperformance. Key risks include shipping industry cyclicality and capital expenditure requirements. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's strong fundamentals against sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
